Business
Achieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026
SEATTLE and VANCOUVER, British Columbia, March 17, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced it will report its fourth quarter and full year 2025 financial results and provide a corporate update on the cytisinicline development program on Tuesday, March 24, 2026, at 8:30 AM EDT. To access the webca
About this update from Achieve Life Sciences, Inc.
[{"type":"image","alt":"Achieve Life Sciences","displaySize":"","headline":null,"caption":"Achieve Life Sciences","className":"","disableSlideshowImg":false,"size":{"original":{"width":269,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/f01e07053436b73353dd8f78efeb68ec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Nz0ojNZV.4IpZgjbhcgTOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQ2ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f01e07053436b73353dd8f78efeb68ec","width":269,"height":300}},"lazy":false},{"type":"text","content":"SEATTLE and VANCOUVER, British Columbia, March 17, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced it will report its fourth quarter and full year 2025 financial results and provide a corporate update on the cytisinicline development program on Tuesday, March 24, 2026, at 8:30 AM EDT.","length":480,"tagName":"p"},{"type":"text","content":"To access the webcast, please use the following link: 4Q25 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and referencing conference ID 13758715. A webcast replay will be available approximately three hours after the call and archived on the website for 90 days.","length":364,"tagName":"p"},{"type":"text","content":"About Achieve Life Sciences, Inc. Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence. In September 2025, the company announced that its New Drug Application, submitted to the U.S. Food and Drug Administration (FDA) in June 2025, had been accepted for review. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of June 20, 2026. The NDA is for cytisinicline to be used as a treatment of nicotine dependence for smoking cessation in adults, based on two successfully completed Phase 3 studies and its open-label safety study. Additionally, the company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication.","length...